REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.18−0.08 (-1.10%)
Close on Nov 19, 2026Market cap $473.98MP/E –Yield –
Regenxbio net income
Net income is the profit left for shareholders after every expense, interest and tax.
Regenxbio's net income for the twelve months ending Jun 30, 2026 was -$196.43M. For fiscal 2025 it was -$193.88M. The highest annual figure on record is $127.84M in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$193.88M | – |
| FY2024 | Dec 31, 2024 | -$227.10M | – |
| FY2023 | Dec 31, 2023 | -$263.49M | – |
| FY2022 | Dec 31, 2022 | -$280.32M | -319.3% |
| FY2021 | Dec 31, 2021 | $127.84M | – |
| FY2020 | Dec 31, 2020 | -$111.25M | – |
| FY2019 | Dec 31, 2019 | -$94.73M | -194.8% |
| FY2018 | Dec 31, 2018 | $99.94M | – |
| FY2017 | Dec 31, 2017 | -$73.17M | – |
| FY2016 | Dec 31, 2016 | -$62.97M | – |
| FY2015 | Dec 31, 2015 | -$22.81M | – |
| FY2014 | Dec 31, 2014 | -$4.00M | – |
| FY2013 | Dec 31, 2013 | -$5.39M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$90.05M | -1580.4% |
| Q4 FY2025 | Dec 31, 2025 | -$67.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$61.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$70.87M | – |
| Q1 FY2025 | Mar 31, 2025 | $6.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$51.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$59.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$52.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$63.33M | – |
| Q4 FY2023 | Dec 31, 2023 | -$62.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$61.87M | – |
| Q2 FY2023 | Jun 30, 2023 | -$72.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$59.94M | -120.4% |
| Q3 FY2022 | Sep 30, 2022 | -$75.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$68.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$76.72M | – |
| Q4 FY2021 | Dec 31, 2021 | $294.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$58.41M | -764.4% |
| Q2 FY2021 | Jun 30, 2021 | -$57.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$50.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$46.24M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.79M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.76M | – |
| Q1 FY2020 | Mar 31, 2020 | -$40.04M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.46M | -714.6% |
| Q3 FY2019 | Sep 30, 2019 | -$34.58M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.46M | -113.8% |
| Q1 FY2019 | Mar 31, 2019 | -$32.23M | -130.9% |
| Q4 FY2018 | Dec 31, 2018 | $4.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.20M | – |
| Q2 FY2018 | Jun 30, 2018 | $10.59M | – |
| Q1 FY2018 | Mar 31, 2018 | $104.24M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$20.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.99M | – |
| Q4 FY2016 | Dec 31, 2016 | -$19.61M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.15M | – |
See a number that looks wrong?